CN111556759A - 早产儿中的粘膜防御和肠道/肺功能的成熟化 - Google Patents

早产儿中的粘膜防御和肠道/肺功能的成熟化 Download PDF

Info

Publication number
CN111556759A
CN111556759A CN201880085608.5A CN201880085608A CN111556759A CN 111556759 A CN111556759 A CN 111556759A CN 201880085608 A CN201880085608 A CN 201880085608A CN 111556759 A CN111556759 A CN 111556759A
Authority
CN
China
Prior art keywords
hbd
defensin
lactoferrin
administration
defensins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880085608.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·诺基德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Defensin Therapeutics ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defensin Therapeutics ApS filed Critical Defensin Therapeutics ApS
Publication of CN111556759A publication Critical patent/CN111556759A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880085608.5A 2017-11-10 2018-11-09 早产儿中的粘膜防御和肠道/肺功能的成熟化 Pending CN111556759A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17201002 2017-11-10
EP17201002.7 2017-11-10
PCT/EP2018/080814 WO2019092201A2 (en) 2017-11-10 2018-11-09 Maturation of mucosal defense and gut/lung function in the preterm infant

Publications (1)

Publication Number Publication Date
CN111556759A true CN111556759A (zh) 2020-08-18

Family

ID=60301879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880085608.5A Pending CN111556759A (zh) 2017-11-10 2018-11-09 早产儿中的粘膜防御和肠道/肺功能的成熟化

Country Status (13)

Country Link
US (2) US20200316172A1 (https=)
EP (1) EP3706773A2 (https=)
JP (1) JP2021502363A (https=)
KR (1) KR20200095472A (https=)
CN (1) CN111556759A (https=)
AU (1) AU2018363783A1 (https=)
BR (1) BR112020009254A2 (https=)
CA (1) CA3082288A1 (https=)
MX (1) MX2020004863A (https=)
RU (1) RU2020115758A (https=)
SG (1) SG11202003868UA (https=)
WO (1) WO2019092201A2 (https=)
ZA (1) ZA202002992B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114903973A (zh) * 2022-04-21 2022-08-16 上海市肺科医院 一种呼吸道粘膜免疫增强药物组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006848A (es) * 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.
PL3713590T3 (pl) * 2017-11-24 2025-09-15 Defensin Therapeutics Aps Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
US20240252558A1 (en) * 2023-01-29 2024-08-01 The University Of Chicago Probiotics to rescue maternal immune activation-induced neurodevelopment deficits
KR20240150943A (ko) 2023-04-10 2024-10-17 (주)인트젠 영유아용 유산균 프로바이오틱스 조성물
CN116868958A (zh) * 2023-09-06 2023-10-13 中国人民解放军军事科学院军事医学研究院 构建缺氧导致肠道应激损伤的动物模型的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201200416A1 (ru) * 2012-03-12 2013-09-30 Аделя Сабир кызы Гаджиева Способ ранней диагностики и лечения некротического энтероколита у новорожденных
WO2017129195A1 (en) * 2016-01-26 2017-08-03 Defensin Therapeutics Aps Methods for modulating intestinal microbiota

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2502324A1 (en) * 2002-10-14 2004-04-29 Lars Thim Glucagon - like peptide - 2 variants
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
SG172709A1 (en) * 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
US20110223137A1 (en) * 2008-12-05 2011-09-15 Nestec S.A. Compositions for use in low-birth weight infants
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
JP6219277B2 (ja) * 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
SG11201406628RA (en) * 2012-04-23 2014-11-27 Chiesi Farma Spa Method and system for the administration of a pulmonary surfactant by atomization
EP2968073B1 (en) * 2013-03-13 2017-08-16 Rush University Medical Center Delivery device for oropharyngeal administration of mother's colostrum and milk
MX2019006848A (es) * 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201200416A1 (ru) * 2012-03-12 2013-09-30 Аделя Сабир кызы Гаджиева Способ ранней диагностики и лечения некротического энтероколита у новорожденных
WO2017129195A1 (en) * 2016-01-26 2017-08-03 Defensin Therapeutics Aps Methods for modulating intestinal microbiota

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SHEILA A ARMOGIDA ET AL.: "Identification and quantification of innate immune system mediators in human breast milk", ALLERGY AND ASTHMA PROCEEDINGS, vol. 25, no. 5, pages 297, XP009150956 *
YINGYING HE ET AL.: "Human Milk Components Modulate Toll-Like Receptor-Mediated Inflammation", ADVANCES IN NUTRITION, vol. 7, no. 1, pages 103 *
刘建红;李晓梅;吕欣;李晓莺;刘向红;: "胃液表皮生长因子与β-防御素在早产儿胃肠功能障碍中作用的临床研究", 中国妇幼保健, no. 24, pages 24 - 25 *
左倩倩;茅双根;: "新生儿坏死性小肠结肠炎发病机制的研究进展", 沈阳医学院学报, no. 6, pages 77 - 79 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114903973A (zh) * 2022-04-21 2022-08-16 上海市肺科医院 一种呼吸道粘膜免疫增强药物组合物
CN114903973B (zh) * 2022-04-21 2025-08-29 上海市肺科医院 一种呼吸道粘膜免疫增强药物组合物

Also Published As

Publication number Publication date
BR112020009254A2 (pt) 2020-10-27
JP2021502363A (ja) 2021-01-28
KR20200095472A (ko) 2020-08-10
MX2020004863A (es) 2020-10-14
US20250009844A1 (en) 2025-01-09
WO2019092201A3 (en) 2019-06-27
ZA202002992B (en) 2021-10-27
RU2020115758A (ru) 2021-12-10
CA3082288A1 (en) 2019-05-16
SG11202003868UA (en) 2020-05-28
US20200316172A1 (en) 2020-10-08
EP3706773A2 (en) 2020-09-16
WO2019092201A2 (en) 2019-05-16
AU2018363783A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
US20250009844A1 (en) Maturation of mucosal defense and gut/lung function in the preterm infant
US20230067261A1 (en) Methods for treating inflammatory conditions of the lungs
Wright Immunoregulatory functions of surfactant proteins
CN112004549B (zh) 用于保护氧敏感革兰氏阳性菌的REG3α
CN102247591A (zh) 使用哺乳动物β防御素的炎性肠病的治疗
JP2014028839A (ja) 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
ES2256070T3 (es) Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana.
Avalos-Gómez et al. Lactoferrin: An effective weapon in the battle against bacterial infections
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
Magrone et al. Antimicrobial peptides in human disease: therapeutic approaches. Second of two parts
JP5048678B2 (ja) 肺感染症および敗血症を防止および処置するための表面活性タンパク質−ｄ
WO2014128173A1 (en) Gm-csf for treatment of chronic oral mucositis
US20150174204A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
US7060677B1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220330

Address after: Denmark bagsvaerd

Applicant after: NOVOZYMES A/S

Address before: Copenhagen, Denmark

Applicant before: DEFENSIN THERAPEUTICS APS

TA01 Transfer of patent application right